Bimatoprost Eye Drops Uses, Side Effects, Dosage | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Bimatoprost
Therapeutic Class: Prostaglandin analogue
Subclass: Antiglaucoma agent
Speciality: Ophthalmology
Schedule (India): Schedule H
Route(s): Ophthalmic (topical)
Formulations Available in India:
• Eye drops: 0.01% w/v (sterile ophthalmic solution, 3 mL bottle)
• Eye drops: 0.03% w/v (sterile ophthalmic solution, 3 mL bottle)
• Fixed-dose combinations with Timolol 0.5% available
• Eye drops: 0.01% w/v (sterile ophthalmic solution, 3 mL bottle)
• Eye drops: 0.03% w/v (sterile ophthalmic solution, 3 mL bottle)
• Fixed-dose combinations with Timolol 0.5% available
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Open-Angle Glaucoma
| Parameter | Details |
|
Starting dose
|
1 drop of 0.03% solution in affected eye(s) once daily in the evening |
|
Titration
|
Not required |
|
Usual maintenance dose
|
1 drop once daily in the evening |
|
Maximum dose
|
Once daily only — more frequent dosing paradoxically reduces efficacy |
|
Clinical notes
|
Onset of action within 4 hours; peak IOP reduction at 8–12 hours; full therapeutic effect may take 2–4 weeks |
2. Ocular Hypertension
| Parameter | Details |
|
Starting dose
|
1 drop of 0.03% solution in affected eye(s) once daily in the evening |
|
Titration
|
Not required |
|
Usual maintenance dose
|
1 drop once daily in the evening |
|
Maximum dose
|
Once daily only |
|
Clinical notes
|
Can be used as monotherapy or adjunctive therapy with beta-blockers or carbonic anhydrase inhibitors; if using multiple eye drops, maintain ≥5 minute interval between administrations |
Secondary Indications – Adults Only (Off-label, if any)
| Indication | Dose | Duration | Notes |
|
Eyelash Hypotrichosis (OFF-LABEL, Specialist-only)
|
Apply thin layer of 0.03% solution to upper eyelid lash margin once daily at night using sterile applicator | 12–16 weeks for visible effect | US FDA-approved for this indication; considered cosmetic in India; not standard ophthalmic use; results reverse upon discontinuation |
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Glaucoma / Ocular Hypertension in Paediatric Patients
| Age Group | Dosing | Notes |
|
≥16 years
|
1 drop once daily in the evening (same as adult dose) | Safety profile similar to adults |
|
3–15 years
|
1 drop once daily in the evening | OFF-LABEL — Limited paediatric data; use under specialist supervision only |
|
<3 years
|
Not recommended | Insufficient safety data |
Monitoring requirements:
• IOP measurement within 2 weeks of initiation
• Monitor for iris pigmentation changes at each visit
• Assess compliance and technique
• IOP measurement within 2 weeks of initiation
• Monitor for iris pigmentation changes at each visit
• Assess compliance and technique
Secondary Indications – Paediatric Doses (Off-label, if any)
• Not applicable — Cosmetic indications not appropriate for paediatric use
General Paediatric Statement
• Not recommended below age 3 years except under paediatric ophthalmologist supervision
• Limited long-term safety data in children
• Permanent iris pigmentation changes may occur
• Limited long-term safety data in children
• Permanent iris pigmentation changes may occur
RENAL ADJUSTMENT
• No dose adjustment required
• Minimal systemic absorption from ophthalmic administration
• No specific studies in dialysis patients — use standard dosing
• Minimal systemic absorption from ophthalmic administration
• No specific studies in dialysis patients — use standard dosing
HEPATIC ADJUSTMENT
| Severity | Recommendation |
|
Mild impairment
|
No dose adjustment required |
|
Moderate impairment
|
No dose adjustment required |
|
Severe impairment
|
Use with caution; limited human data; minimal systemic exposure expected |
CONTRAINDICATIONS
• Known hypersensitivity to bimatoprost, benzalkonium chloride, or any component of formulation
• Active intraocular inflammation (uveitis, iritis)
• Aphakia with torn posterior lens capsule
• Pseudophakia with torn posterior lens capsule or anterior chamber intraocular lens
• Active intraocular inflammation (uveitis, iritis)
• Aphakia with torn posterior lens capsule
• Pseudophakia with torn posterior lens capsule or anterior chamber intraocular lens
CAUTIONS
• History of uveitis or iritis — may exacerbate inflammation
• Pre-existing macular oedema or risk factors for cystoid macular oedema (diabetic retinopathy, retinal vein occlusion, post-cataract surgery)
• History of herpetic keratitis — may reactivate
• Patients with mixed-colour irides — higher risk of permanent iris pigmentation
• Unilateral use — may cause noticeable asymmetry in iris colour, eyelash appearance, and periorbital skin
• Contact lens wearers — remove lenses before instillation; reinsert after 15 minutes
• Patients with corneal endothelial disease
• Pre-existing macular oedema or risk factors for cystoid macular oedema (diabetic retinopathy, retinal vein occlusion, post-cataract surgery)
• History of herpetic keratitis — may reactivate
• Patients with mixed-colour irides — higher risk of permanent iris pigmentation
• Unilateral use — may cause noticeable asymmetry in iris colour, eyelash appearance, and periorbital skin
• Contact lens wearers — remove lenses before instillation; reinsert after 15 minutes
• Patients with corneal endothelial disease
PREGNANCY
| Parameter | Recommendation |
|
Safety category
|
Avoid unless essential — Prostaglandin analogues may have uterotonic effects |
|
Preferred alternatives
|
Timolol eye drops (beta-blocker) — better safety profile in pregnancy |
|
When used
|
Only if potential benefit justifies potential risk; specialist ophthalmology and obstetric input required |
|
Monitoring
|
IOP control; routine fetal surveillance (no additional monitoring typically required due to minimal systemic absorption) |
LACTATION
| Parameter | Recommendation |
|
Compatibility
|
Likely compatible — minimal systemic absorption expected |
|
Preferred alternatives
|
Timolol eye drops if concerns persist |
|
Expected drug levels in milk
|
Negligible (minimal systemic absorption from ophthalmic route) |
|
Infant monitoring
|
Observe for feeding difficulties, unusual sedation, rash (unlikely) |
ELDERLY
| Parameter | Recommendation |
|
Starting dose
|
Same as general adult dose (1 drop once daily in evening) |
|
Titration
|
Not required |
|
Special risks
|
Higher prevalence of ocular comorbidities (pseudophakia, macular disease); monitor for cystoid macular oedema |
|
Monitoring
|
Regular IOP and macular assessment |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Recommendation |
|
Other prostaglandin analogues (latanoprost, travoprost, tafluprost)
|
Concurrent use may paradoxically increase IOP | Avoid concomitant use of multiple prostaglandin analogues |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Recommendation |
|
Topical NSAIDs (ketorolac, nepafenac)
|
May enhance ocular inflammatory response | Monitor for cystoid macular oedema, especially post-cataract surgery |
|
Topical corticosteroids
|
May mask signs of ocular inflammation | Monitor IOP and inflammatory signs |
|
Other antiglaucoma agents (timolol, brimonidine, dorzolamide)
|
Additive IOP-lowering effect (desirable) | Administer at least 5 minutes apart; commonly used together |
|
Benzalkonium chloride-containing products
|
Cumulative ocular surface toxicity | Limit total exposure; consider preservative-free alternatives if using multiple drops |
COMMON ADVERSE EFFECTS
• Conjunctival hyperaemia (most common, up to 45%)
• Eyelash changes (increased length, thickness, pigmentation, number)
• Ocular pruritus
• Eye dryness
• Burning or stinging sensation
• Foreign body sensation
• Periorbital skin darkening
• Eyelid erythema
• Eyelash changes (increased length, thickness, pigmentation, number)
• Ocular pruritus
• Eye dryness
• Burning or stinging sensation
• Foreign body sensation
• Periorbital skin darkening
• Eyelid erythema
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Action |
|
Iris pigmentation (irreversible)
|
Counsel patient; more common in mixed-colour irides; may cause permanent heterochromia with unilateral use |
|
Cystoid macular oedema
|
Discontinue; refer for retinal evaluation; more common in aphakic/pseudophakic patients |
|
Uveitis/Iritis
|
Discontinue immediately; refer for specialist management |
|
Herpetic keratitis reactivation
|
Discontinue; antiviral therapy |
|
Periorbital fat atrophy (prostaglandin-associated periorbitopathy)
|
May cause enophthalmos, deepening of upper eyelid sulcus; consider switching to alternative class |
MONITORING REQUIREMENTS
| Timing | Parameters |
|
Baseline
|
IOP measurement; iris colour documentation (photograph if possible); lens status; macular assessment in high-risk patients; history of uveitis/herpetic keratitis |
|
After initiation (2–4 weeks)
|
IOP measurement; assess for hyperaemia, tolerance |
|
Short-term (1–3 months)
|
IOP measurement monthly until stable; monitor iris and periocular changes |
|
Long-term
|
IOP every 3–6 months; annual macular examination in high-risk patients (pseudophakia, diabetic retinopathy); document any iris colour changes |
BRANDS AVAILABLE IN INDIA
Single-agent formulations:
• Lumigan (Allergan)
• Careprost (Sun Pharma)
• Bimat (Ajanta Pharma)
• Xovatra (Cipla)
• Bimato (Micro Labs)
• 3 Lat (Allergan — 0.01% formulation)
• Lumigan (Allergan)
• Careprost (Sun Pharma)
• Bimat (Ajanta Pharma)
• Xovatra (Cipla)
• Bimato (Micro Labs)
• 3 Lat (Allergan — 0.01% formulation)
Fixed-dose combinations (Bimatoprost + Timolol 0.5%):
• Lumigan-T (Allergan)
• Bimat-T (Ajanta Pharma)
• Xovatra-T (Cipla)
• Lumigan-T (Allergan)
• Bimat-T (Ajanta Pharma)
• Xovatra-T (Cipla)
PRICE RANGE (INR)
| Formulation | Pack Size | Price Range |
| Bimatoprost 0.03% eye drops | 3 mL | ₹200–₹600 |
| Bimatoprost 0.01% eye drops | 3 mL | ₹250–₹500 |
| Bimatoprost + Timolol FDC | 3 mL | ₹300–₹700 |
• Not listed under NLEM
• Not under NPPA price control
• Significant price variation between branded and generic products
• Not under NPPA price control
• Significant price variation between branded and generic products
CLINICAL PEARLS
• Evening dosing is optimal — Prostaglandin analogues have greater IOP-lowering effect when administered in the evening
• Do not exceed once-daily dosing — More frequent instillation paradoxically reduces efficacy due to receptor downregulation
• Warn patients about permanent pigmentation — Iris darkening is irreversible; particularly important in unilateral use (may cause heterochromia)
• Consider 0.01% formulation — Similar efficacy with potentially fewer hyperaemia-related side effects
• Contact lens guidance — Remove lenses before instillation; wait 15 minutes before reinserting (benzalkonium chloride is absorbed by soft lenses)
• Prostaglandin-associated periorbitopathy (PAP) — Consider if patient develops deepening of upper lid sulcus, enophthalmos, or periorbital hollowing; may need to switch drug class
• Post-cataract surgery caution — Higher risk of cystoid macular oedema; monitor closely; may need to temporarily discontinue
• Do not exceed once-daily dosing — More frequent instillation paradoxically reduces efficacy due to receptor downregulation
• Warn patients about permanent pigmentation — Iris darkening is irreversible; particularly important in unilateral use (may cause heterochromia)
• Consider 0.01% formulation — Similar efficacy with potentially fewer hyperaemia-related side effects
• Contact lens guidance — Remove lenses before instillation; wait 15 minutes before reinserting (benzalkonium chloride is absorbed by soft lenses)
• Prostaglandin-associated periorbitopathy (PAP) — Consider if patient develops deepening of upper lid sulcus, enophthalmos, or periorbital hollowing; may need to switch drug class
• Post-cataract surgery caution — Higher risk of cystoid macular oedema; monitor closely; may need to temporarily discontinue
TAGS
bimatoprost; glaucoma; ocular hypertension; prostaglandin analogue; IOP-lowering; iris pigmentation; ophthalmology; Schedule H; renal-safe; pregnancy-caution
VERSION
RxIndia v0.1 — 03 Feb 2026
REFERENCES
• CDSCO — Approved product labels
• Indian Pharmacopoeia / NFI 2016
• API Textbook of Medicine — Ophthalmology section
• AIIMS Ophthalmology Department protocols
• Harrison’s Principles of Internal Medicine, 21st edition
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th edition
• Peer-reviewed studies on prostaglandin analogues in glaucoma management
• Indian Pharmacopoeia / NFI 2016
• API Textbook of Medicine — Ophthalmology section
• AIIMS Ophthalmology Department protocols
• Harrison’s Principles of Internal Medicine, 21st edition
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th edition
• Peer-reviewed studies on prostaglandin analogues in glaucoma management
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.